This study aims to observe the efficacy and safety of the combination of vebecotototo monoclonal antibody and putli monoclonal antibody in the treatment of EGFR-positive refractory biliary malignant tumors.
Age 18 to 75 years, regardless of gender;
Patients with locally advanced or metastatic biliary tract malignancies confirmed by histopathological or cytological examination;
Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1;
EGFR immunohistochemistry (IHC) score ≥1+ as assessed by pathology laboratory;
History of another malignant tumor diagnosed within the past 5 years (except carcinoma in situ, basal cell carcinoma, etc.);
Known central nervous system metastasis (except those with stable disease control and no symptoms after radiotherapy or surgery for at least 4 weeks), or evidence of carcinomatous meningitis;
Presence of psychiatric or neurological disorders preventing cooperation;
Prior exposure to ADC drugs carrying MMAE payload;